Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment.
about
Pathogenesis, management and prevention of atypical femoral fracturesPeriprosthetic bone loss: diagnostic and therapeutic approachesAmerican Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures.Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta.The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronateBisphosphonate-induced reductions in rat femoral bone energy absorption and toughness are testing rate-dependentSubtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group ReportDisruption of bone development and homeostasis by trisomy in Ts65Dn Down syndrome mice.Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandible.Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogsArthritis induces early bone high turnover, structural degradation and mechanical weakness.Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogsMechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjectsCell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation.Alendronate does not prevent long bone fragility in an inactive rat model.Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.Research perspectives: The 2013 AAOS/ORS research symposium on Bone Quality and Fracture Prevention.Reference-point indentation correlates with bone toughness assessed using whole-bone traditional mechanical testing.Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality.Absence of Cx43 selectively from osteocytes enhances responsiveness to mechanical force in miceDeletion of Cx43 from osteocytes results in defective bone material properties but does not decrease extrinsic strength in cortical boneShort-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness.Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk.A Case Report of Bisphosphonate-induced Bilateral Osteoporotic Subtrochanteric Fracture Femurii: Review of Literature.High bone mass in mice lacking Cx37 because of defective osteoclast differentiation.Fracture risk associated with chronic use of bisphosphonates: evidence today.The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.Bone Material Properties and Skeletal Fragility.Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model.Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report.Control of Bone Anabolism in Response to Mechanical Loading and PTH by Distinct Mechanisms Downstream of the PTH Receptor.Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits.Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization.Three years of alendronate treatment does not continue to decrease microstructural stresses and strains associated with trabecular microdamage initiation beyond those at 1 year.Proximal femoral reconstruction for failed internal fixation of a bisphosphonate-related femur fracture.Simultaneous, bilateral, complete atypical femoral fractures after long-term alendronate use.Cx43 overexpression in osteocytes prevents osteocyte apoptosis and preserves cortical bone quality in aging mice.
P2860
Q26824555-44D77795-BA86-4274-9444-26E0B1C8F413Q27024847-DA8ACEB4-2296-48C0-9102-5E358C10AF9CQ27027254-D2A758A0-102D-4D89-A00F-BBECF05850E0Q30463549-0FC1C334-98DE-4E7F-86EC-92F405226EDAQ33700394-1ED71247-53B5-4C07-803C-D75BD4B6907FQ33723995-C59719DF-2524-4C77-98E4-D9A740628520Q34486831-29E08CBC-8E5E-44DF-8D04-AC1E23BDBDB2Q34494004-6C2833BC-17E6-47E0-ABF9-1B9C60B5AFD6Q34635733-08C9AF33-0A45-44A4-94A2-7E809931A518Q34758541-31666CE1-A5B0-4A4E-B9DA-0BBA524E74D7Q35008944-0CA9D169-B6E8-495C-A557-E916C76618CCQ35156035-CDFBB07B-4E66-477D-8DC9-07279E121A8FQ35566438-02928281-9F09-437E-84DE-DFEEE380E2F6Q35729489-9934D976-C67F-4D69-AF7B-6E643A94E3D8Q35811110-9ECDCCD6-338D-48E1-9B5C-02A051B791B2Q36472781-781BEA31-C041-4131-A7FF-2B6BE38DA2CBQ36473294-CD781EE5-F315-4870-A3D4-5C0110B2C6E2Q36584474-73DA8A0B-15D8-4E52-B490-724370F63E4DQ36633388-7F1B2CBA-D722-4EC3-BEA6-5F807F55BE9DQ36874711-9CADF81D-D7AB-4C6A-ADF0-2F55AAC89467Q37059660-470CC835-3F75-4838-8760-DA1183E1749DQ37067163-5C30E758-C325-47EA-8974-98BC6ECD6DB5Q37323596-0F95026E-3A84-4F79-9618-30610779AA6DQ37356300-04ABC092-4433-451B-8A30-F89550DC1828Q37620378-946F6A09-43E8-4DD5-B7A9-4A6B46032A50Q37653316-F3F16DC1-2616-443D-8893-9E941A3543CBQ37814414-6104FA3E-6211-4991-9488-193B1D8BB694Q37832692-6C808811-9399-496C-A410-57EDF26D9BCAQ38458050-11416F0C-AB2B-45D3-8DBE-9EA26CD3225FQ38632055-91814871-C731-441F-87AA-E5F0AFECFAF5Q39625860-936C4E7B-72A1-44B1-94EC-F7932E6A0702Q42500075-593664FB-8BD7-4707-A021-641E306831AFQ45997666-979ED391-B182-4B11-AB7C-5CEB375633EBQ46292054-7967BB3B-0211-4795-8583-19BC6D20E1EBQ50504521-78E873E8-9812-4812-B656-110CEFEF564FQ54286879-DCDDBF53-0F41-440F-87EF-E6103C1B85FEQ55400006-41A6F7DC-07ED-4F84-8771-09E897ECDA0CQ55518200-9A7578C5-DDC2-493C-909E-F322884806F3
P2860
Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Alendronate reduces bone tough ...... ng 3 years of daily treatment.
@en
Alendronate reduces bone tough ...... ng 3 years of daily treatment.
@nl
type
label
Alendronate reduces bone tough ...... ng 3 years of daily treatment.
@en
Alendronate reduces bone tough ...... ng 3 years of daily treatment.
@nl
prefLabel
Alendronate reduces bone tough ...... ng 3 years of daily treatment.
@en
Alendronate reduces bone tough ...... ng 3 years of daily treatment.
@nl
P2860
P1476
Alendronate reduces bone tough ...... ing 3 years of daily treatment
@en
P2093
David B Burr
Susan Reinwald
P2860
P2888
P304
P356
10.1007/S00223-008-9131-8
P407
P577
2008-05-08T00:00:00Z